COMMUNIQUÉS West-GlobeNewswire
-
InhaleH₂ Earns Canadian SR&ED Recognition for Breakthrough in Hydrogen Therapy Delivery
25/03/2026 -
CROSSJECT nomme Lionel SELTZ au poste de Directeur Administratif et Financier
25/03/2026 -
Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration
25/03/2026 -
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
25/03/2026 -
Jushi Holdings Inc. Announces First Settlement in Ongoing Hemp-Derived THC Litigation
25/03/2026 -
Acentra Health Names New Senior Vice Presidents, Mohamed Karama and Nirav Dalal, to Drive Company Growth and Business Development
25/03/2026 -
BeyondSpring Reports 2025 Year-End Financial Results
25/03/2026 -
Eascra Biotech Takes First Place at TechConnect Bio in Space Innovation Challenge
25/03/2026 -
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
25/03/2026 -
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
25/03/2026 -
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
25/03/2026 -
Declaration de NANOBIOTIX concernant une recente rumeur mediatique
25/03/2026 -
SEMCAP Launches SEMCAP Beauty & Wellness to Capitalize on Opportunities in Burgeoning Longevity and Consumer Wellbeing Space
25/03/2026 -
VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral Presentation at ARVO 2026
25/03/2026 -
SRx Health Solutions Hedges Decentralized Finance (DeFi) Portfolio with Investment in Gold and Reduces its Emerging Market Hedge
25/03/2026 -
VIVUS Reinforces QSIVA®’s Clinical Efficacy and Safety in Obesity Management
25/03/2026 -
Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
25/03/2026 -
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
25/03/2026 -
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
25/03/2026
Pages